The PE Ratio as of November 2024 (TTM) for Cardiff Oncology, Inc. (CRDF) is -3.35

According to Cardiff Oncology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.35. This represents a change of 5.09% compared to the average of -3.19 of the last 4 quarters.

Cardiff Oncology, Inc. (CRDF) Historical PE Ratio (quarterly & annually)

How has CRDF PE Ratio performed in the past?

The mean historical PE Ratio of Cardiff Oncology, Inc. over the last ten years is -4.49. The current -3.35 PE Ratio has changed 7.35% with respect to the historical average. Over the past ten years (40 quarters), CRDF's PE Ratio was at its highest in in the June 2018 quarter at -0.38. The PE Ratio was at its lowest in in the September 2020 quarter at -18.41.

Cardiff Oncology, Inc. (CRDF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cardiff Oncology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cardiff Oncology, Inc. (CRDF) Average PE Ratio

How has CRDF PE Ratio performed in the past?

The current PE Ratio of Cardiff Oncology, Inc. (CRDF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Cardiff Oncology, Inc. (CRDF) PE Ratio vs. Peers

How is CRDF’s PE Ratio compared to its peers?

Cardiff Oncology, Inc.’s PE Ratio is less than Reviva Pharmaceuticals Holdings, Inc. (-0.96), less than eFFECTOR Therapeutics, Inc. (-0.00), less than PDS Biotechnology Corporation (-2.97), less than Navidea Biopharmaceuticals, Inc. (0.03), less than Reviva Pharmaceuticals Holdings, Inc. (-0.96), less than Eyenovia, Inc. (-0.70), less than Cognition Therapeutics, Inc. (-0.65), less than TransCode Therapeutics, Inc. (-0.18), less than Kodiak Sciences Inc. (-1.31), less than SELLAS Life Sciences Group, Inc. (-2.06), greater than NLS Pharmaceutics AG (-81.00), greater than Mereo BioPharma Group plc (-17.93), less than Aravive, Inc. (-0.04), greater than Day One Biopharmaceuticals, Inc. (-18.95), less than IN8bio, Inc. (-0.49), less than Cue Biopharma, Inc. (-1.84), less than Lantern Pharma Inc. (-2.16), greater than Gracell Biotechnologies Inc. (-12.42), greater than Cullinan Oncology, Inc. (-6.51), less than Bolt Biotherapeutics, Inc. (-0.37), less than Lyra Therapeutics, Inc. (-0.17), greater than Autolus Therapeutics plc (-4.24),

Build a custom stock screener for Cardiff Oncology, Inc. (CRDF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiff Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cardiff Oncology, Inc. (CRDF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cardiff Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.